BIOCRYST PHARMACEUTICALS, INC.

BCRX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2009
Revenue $74.6M
Cost of Revenue $4.5M
Gross Profit $70.0M
Gross Margin 93.9%
Operating Expenses
Research & Development $73.7M
SG&A Expense $10.1M
Operating Income $-13.7M
Operating Margin -18.4%
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-13.5M
Net Margin -18.0%
EPS (Basic) $-0.35
EPS (Diluted) $-0.35
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 3 of 3 Older →